Skip to main content

Table 3 Relative risks (RR) of breast cancer death associated with each risk classifier among ER-positive patients, stratified by treatment with tamoxifen.

From: HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease

 

Cases

Controls

    

Risk classifier

n

%

n

%

RR1

95% CI

RR2

95% CI

Tamoxifen treated (49 cases and 112 controls)

   HOXB13:IL17BR

        

Low risk

19

39%

58

52%

1.0

ref

1.0

ref

High risk

30

61%

54

48%

1.9

0.9 - 3.7

1.5

0.7 - 3.2

   MGI

        

Low risk

12

24%

55

49%

1.0

ref

1.0

ref

High risk

37

76%

57

51%

2.9

1.3 - 6.2

2.1

0.8 - 5.5

   MGI+HOXB13:IL17BR

        

Low risk

12

24%

55

49%

1.0

ref

1.0

ref

Intermediate risk

14

29%

31

28%

1.8

0.7 - 4.8

1.3

0.4 - 4.2

High risk

23

47%

26

23%

3.5

1.5 - 8.1

2.7

0.9 - 7.5

   BCI

        

Low risk

13

27%

61

54%

1.0

ref

1.0

ref

Intermediate risk

15

31%

29

26%

2.2

0.9 - 5.6

2.1

0.8 - 6.0

High risk

21

43%

22

20%

4.2

1.7 - 10.3

3.3

1.1 - 10.3

Tamoxifen untreated (90 cases and 174 controls)

   HOXB13:IL17BR

        

Low risk

41

46%

101

58%

1.0

ref

1.0

ref

High risk

49

54%

73

42%

1.6

1.0 - 2.7

1.3

0.8 - 2.3

   MGI

        

Low risk

32

36%

99

57%

1.0

ref

1.0

ref

High risk

58

64%

75

43%

2.6

1.5 - 4.8

1.7

0.8 - 3.4

   MGI+HOXB13:IL17BR

        

Low risk

32

36%

99

57%

1.0

ref

1.0

ref

Intermediate risk

27

30%

39

22%

2.5

1.3 - 4.8

1.7

0.8 - 3.6

High risk

31

34%

36

21%

2.9

1.4 - 5.8

1.6

0.7 - 3.8

   BCI

        

Low risk

30

33%

108

62%

1.0

ref

1.0

ref

Intermediate risk

26

29%

28

16%

3.9

1.9 - 8.0

3.2

1.5 - 6.8

High risk

34

38%

38

22%

3.6

1.8 - 7.4

2.0

0.8 - 4.9

  1. 1Univariate conditional logistic regression models include HOXB13:IL17BR, MGI, MGI+HOXB13:IL17BR or BCI; 2multivariable conditional logistic regression models include HOXB13:IL17BR, MGI, MGI+HOXB13:IL17BR or BCI plus tumor size (≤2.0,>2.0) and grade (well, intermediate, poor).